Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CORZIDE vs ALDORIL D50
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combination of a beta-adrenergic receptor antagonist (nadolol) and a thiazide diuretic (bendroflumethiazide). Nadolol non-selectively blocks beta-1 and beta-2 receptors, reducing heart rate, myocardial contractility, and blood pressure. Bendroflumethiazide inhibits sodium-chloride symporter in the distal convoluted tubule, increasing excretion of sodium, chloride, and water.
Aldoril D50 is a combination of methyldopa and hydrochlorothiazide. Methyldopa is a centrally-acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brainstem, decreasing peripheral vascular resistance and blood pressure. Hydrochlorothiazide is a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, reducing plasma volume and further lowering blood pressure.
Hypertension
Hypertension (first-line or second-line therapy),Hypertensive urgency (off-label)
Oral: 1 tablet daily containing nadolol 40 mg and bendroflumethiazide 5 mg. May increase to 2 tablets daily if needed.
1 tablet (hydrochlorothiazide 25 mg + methyldopa 250 mg) orally twice daily; maximum dose: 2 tablets (50 mg + 500 mg) twice daily.
Nadolol: 14-24 hours (prolonged in renal impairment up to 45 hours); bendroflumethiazide: 8-9 hours (may be prolonged in renal dysfunction).
3–6 hours (terminal elimination half-life); clinical context: requires twice-daily dosing for sustained blood pressure control; prolonged in renal impairment.
Nadolol: not extensively metabolized, excreted unchanged in urine. Bendroflumethiazide: minimally metabolized, excreted unchanged in urine.
Methyldopa is extensively metabolized in the liver via conjugation and O-methylation, with involvement of catechol-O-methyltransferase (COMT). Hydrochlorothiazide is not extensively metabolized; it is eliminated largely unchanged by the kidneys.
Nadolol: ~73% excreted unchanged in urine via glomerular filtration; bendroflumethiazide: ~30% excreted unchanged in urine, remainder as metabolites via renal and biliary routes.
Renal: 50% as unchanged drug and 20% as metabolites; biliary/fecal: ~25% (as metabolites); total renal clearance accounts for ~70% of elimination.
Nadolol: <30% bound to albumin; bendroflumethiazide: ~94% bound to albumin.
~20% bound to albumin; minimal binding to other plasma proteins.
Nadolol: 1.9-2.5 L/kg (low, consistent with hydrophilic nature); bendroflumethiazide: not well characterized but estimated ~0.5-1 L/kg (small Vd due to high protein binding).
0.2–0.3 L/kg (moderately low Vd, indicating limited extravascular distribution and predominantly plasma water distribution).
Nadolol: ~30-40% (variable, first-pass metabolism minimal); bendroflumethiazide: bioavailability ~65% (oral).
Oral: 30–40% (due to extensive first-pass metabolism); IV: 100%.
GFR 30-50 m L/min: administer every 24 hours; GFR 10-29 m L/min: administer every 24-36 hours; GFR <10 m L/min: administer every 48 hours.
Contraindicated if GFR < 30 m L/min; for GFR 30-50 m L/min: reduce dose and monitor electrolytes.
Child-Pugh Class B or C: use with caution; consider dose reduction or increased monitoring due to reduced clearance.
Child-Pugh Class A: no adjustment; Class B: reduce dose by 50% and monitor; Class C: contraindicated.
Not recommended for use in pediatric patients due to lack of safety and efficacy data.
Not recommended; inadequate safety data.
Start at lower dose (e.g., 1 tablet containing nadolol 20 mg and bendroflumethiazide 2.5 mg) and titrate slowly; monitor renal function and electrolytes.
Start with 1 tablet (hydrochlorothiazide 12.5 mg + methyldopa 125 mg) once daily; increase slowly; monitor for hypotension and electrolyte imbalance.
None
None
Bronchospasm in patients with asthma/COPD,Heart failure exacerbation,Peripheral vascular disease worsening,Abrupt withdrawal may cause angina or MI,Masking of hypoglycemia in diabetics,Electrolyte disturbances (hypokalemia, hyponatremia),Increased BUN and serum creatinine,Orthostatic hypotension,Systemic lupus erythematosus exacerbation
Sedation and drowsiness common; avoid driving or hazardous activities. Risk of Coombs-positive hemolytic anemia with methyldopa (discontinue if anemia develops). Hepatotoxicity and liver function abnormalities (discontinue if jaundice occurs). Orthostatic hypotension; caution in volume-depleted patients. Electrolyte imbalances (particularly hypokalemia, hyponatremia) with hydrochlorothiazide; monitor serum electrolytes. Sulfonamide cross-sensitivity possible. Exacerbation of systemic lupus erythematosus. Avoid abrupt withdrawal of methyldopa (may cause rebound hypertension).
Bronchial asthma,Sinus bradycardia,Heart block greater than first degree,Cardiogenic shock,Uncompensated heart failure,Anuria,Hypersensitivity to thiazides or sulfonamides
Active hepatic disease (cirrhosis, hepatitis) associated with methyldopa therapy; previous methyldopa-induced liver disorders. Anuria or hypersensitivity to thiazide diuretics or sulfonamide-derived drugs. Concomitant use with MAO inhibitors. Severe renal impairment (creatinine clearance <30 m L/min) or electrolyte depletion due to hydrochlorothiazide. Concurrent lithium therapy (risk of lithium toxicity).
Avoid potassium-rich foods (bananas, oranges, spinach, potatoes) in excess unless directed by a physician, as thiazides may cause hypokalemia, but monitoring is needed. Alcohol may potentiate hypotensive effects. Grapefruit juice may increase nadolol levels; avoid concurrent intake.
Avoid potassium supplements or salt substitutes containing potassium without consulting doctor. Limit alcohol intake. Avoid excessive grapefruit juice. Maintain adequate potassium intake through diet to prevent hypokalemia.
CORZIDE (nadolol/bendroflumethiazide) is associated with fetal risk. First trimester: Potential teratogenic effects including hypospadias and neural tube defects with bendroflumethiazide; β-blocker use may increase risk of intrauterine growth restriction. Second trimester: Continued risk of placental insufficiency. Third trimester: Neonatal bradycardia, hypoglycemia, hypotension, and respiratory depression due to nadolol; electrolyte disturbances and volume depletion from bendroflumethiazide.
Hydrochlorothiazide (HCTZ) is Pregnancy Category B in first trimester and Category D in second/third trimesters. Methyldopa (M) is Category B. HCTZ use in second/third trimester may cause fetal/neonatal effects including electrolyte disturbances, jaundice, thrombocytopenia, and possible fetal growth restriction. Methyldopa has not shown teratogenicity. Aldoril D50 (M 500mg/HCTZ 50mg) is not recommended during pregnancy, especially after first trimester.
Nadolol is excreted into breast milk with a relative infant dose of approximately 2-5% of maternal weight-adjusted dose; M/P ratio not well defined. Bendroflumethiazide also appears in breast milk. Consider risk of infant bradycardia, hypotension, and electrolyte disturbances. Avoid use or monitor infant for adverse effects.
Both methyldopa and HCTZ are excreted in breast milk. Methyldopa M/P ratio approximately 1.0; HCTZ M/P ratio variable, small amounts. Use during breastfeeding may suppress lactation due to HCTZ diuretic effect. Monitor infant for signs of hypotension, electrolyte imbalance. Caution recommended; use only if clearly needed.
No established dose adjustment guidelines. Consider reducing nadolol dose due to increased plasma volume and clearance in pregnancy. Bendroflumethiazide typically avoided in pregnancy; if used, monitor for volume depletion and electrolyte imbalance, and consider dose reduction. Clinical judgment required.
Pregnancy-induced increase in plasma volume may reduce effectiveness of HCTZ, requiring dose adjustment. Methyldopa pharmacokinetics not significantly altered; however, increased clearance in pregnancy may require higher doses. In preeclampsia, dose adjustments may be needed. Avoid HCTZ in pregnancy if possible.
Corzide (bendroflumethiazide/nadolol) combines a thiazide diuretic and a non-selective beta-blocker. Monitor for bradycardia, hypotension, hypokalemia, and hyperglycemia. Avoid abrupt withdrawal due to beta-blocker rebound. Use cautiously in asthma, COPD, diabetes, and peripheral vascular disease. Dosage adjustments needed in renal impairment.
ALDORIL D50 combines methyldopa and hydrochlorothiazide. Monitor for orthostatic hypotension, especially in volume-depleted patients. May cause positive Coombs test, hemolytic anemia, and lupus-like syndrome. Avoid in pheochromocytoma. Use caution in hepatic disease.
Take exactly as prescribed, usually once daily in the morning to avoid nighttime urination.,Do not stop taking this medication suddenly; abrupt cessation can cause chest pain or heart attack.,Avoid alcohol, which can increase dizziness and drowsiness.,Report symptoms of low potassium (muscle cramps, weakness) or slow heart rate (dizziness, fainting).,May cause dizziness or lightheadedness; rise slowly from sitting or lying positions.,Use sunscreen and protective clothing as this medication may increase sensitivity to sunlight.
Take exactly as prescribed; do not skip doses or double up.,May cause dizziness or drowsiness; avoid driving until you know how it affects you.,Report unexplained fever, jaundice, or dark urine immediately.,Avoid sudden discontinuation; may cause rapid increase in blood pressure.,Stay hydrated but do not overhydrate; monitor for signs of electrolyte imbalance.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CORZIDE vs ALDORIL D50, answered by our medical review team.
CORZIDE is a Antihypertensive combination that works by Combination of a beta-adrenergic receptor antagonist (nadolol) and a thiazide diuretic (bendroflumethiazide). Nadolol non-selectively blocks beta-1 and beta-2 receptors, reducing heart rate, myocardial contractility, and blood pressure. Bendroflumethiazide inhibits sodium-chloride symporter in the distal convoluted tubule, increasing excretion of sodium, chloride, and water.. ALDORIL D50 is a Antihypertensive Combination that works by Aldoril D50 is a combination of methyldopa and hydrochlorothiazide. Methyldopa is a centrally-acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brainstem, decreasing peripheral vascular resistance and blood pressure. Hydrochlorothiazide is a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, reducing plasma volume and further lowering blood pressure.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CORZIDE and ALDORIL D50 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CORZIDE is: Oral: 1 tablet daily containing nadolol 40 mg and bendroflumethiazide 5 mg. May increase to 2 tablets daily if needed.. The standard adult dose of ALDORIL D50 is: 1 tablet (hydrochlorothiazide 25 mg + methyldopa 250 mg) orally twice daily; maximum dose: 2 tablets (50 mg + 500 mg) twice daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CORZIDE and ALDORIL D50 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CORZIDE is classified as Category C. CORZIDE (nadolol/bendroflumethiazide) is associated with fetal risk. First trimester: Potential teratogenic effects including hypospadias and neural tube defects with bendroflumeth. ALDORIL D50 is classified as Category C. Hydrochlorothiazide (HCTZ) is Pregnancy Category B in first trimester and Category D in second/third trimesters. Methyldopa (M) is Category B. HCTZ use in second/third trimester ma. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.